|
Market Closed -
Euronext Bruxelles
11:55:00 2026-10-06 EDT
|
5-day change | 1st Jan Change | ||
| 202.30 EUR | +0.70% |
|
-4.80% | -15.21% |
| 09-30 | Merck's experimental skin disease drug succeeds in mid-stage study | RE |
| 09-29 | UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session | CI |
| Market Cap | 38.57B 43.42B 36.13B 32.72B 61.7B 4,185B 62.2B 434B 169B 2,135B 163B 159B 6,868B | P/E 2026 * |
20.2x | P/E 2027 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise Value | 38.98B 43.89B 36.51B 33.07B 62.36B 4,230B 62.86B 438B 170B 2,158B 165B 161B 6,942B | EV / Sales 2026 * |
4.5x | EV / Sales 2027 * | 3.84x |
| Free-Float |
61.59% | Yield 2026 * |
0.72% | Yield 2027 * | 0.74% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Bruxelles
| UCB | Real-time | |
CBOE
| UCB | Real-time | |
|
Tradegate
| UNC | Real-time | |
|
Deutsche Boerse AG
| UNC | Delayed | |
|
OTC Markets
| UCBJF | Delayed | |
|
Boerse Muenchen
| UNC | Real-time | |
|
Xetra
| UNC | Delayed | |
|
London S.E.
| 0NZT | Delayed | |
|
CBOE
| 0NZT | Real-time | |
|
Wiener Boerse
| UCB | End-of-day quote | |
|
Börse Stuttgart
| UNC | Delayed | |
|
Borsa Italiana
| 4UCB | End-of-day quote |
Last Transcript: UCB
| 1 day | +0.70% | ||
| 1 week | -4.80% | ||
| Current month | -1.37% | ||
| 1 month | -3.94% | ||
| 3 months | -22.04% | ||
| 6 months | -23.52% | ||
| Current year | -15.21% |
| 1 week | 198.75 |  | 208.65 |
| 1 month | 198.75 | | 217.1 |
| Current year | 198.75 | | 289.5 |
| 1 year | 198.75 | | 289.5 |
| 3 years | 65.4 | | 289.5 |
| 5 years | 65.4 | | 289.5 |
| 10 years | 54.84 | | 289.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 2014-12-31 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 2020-06-30 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 2024-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 2011-12-31 | |
| Director/Board Member | 67 | 2014-12-31 | |
| Director/Board Member | 56 | 2014-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Exercice | Executive/Senior Manager | 3,000 | 0.0015% | ||
| 1/15/26 | Buy | Director | 500 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.70% | -4.80% | -19.72% | +160.49% | 42.94B | |
| +1.26% | -2.30% | +37.82% | +113.76% | 1,019B | |
| +0.73% | -6.31% | +35.06% | +62.14% | 610B | |
| +0.35% | +0.15% | +14.01% | +80.87% | 470B | |
| +1.72% | -4.54% | +59.14% | +37.01% | 344B | |
| +0.26% | -1.58% | +21.97% | +41.79% | 336B | |
| +0.60% | -3.48% | +11.37% | +34.33% | 266B | |
| +1.65% | -4.27% | -5.47% | +9.69% | 241B | |
| -0.09% | -3.71% | +35.15% | +51.88% | 218B | |
| -0.28% | -5.24% | +27.99% | +93.08% | 179B | |
| Average | +0.44% | -3.81% | +21.73% | +68.50% | 372.58B | |
| Weighted average by Cap. | +0.33% | -3.53% | +28.92% | +71.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.66B 9.75B 8.11B 7.34B 13.85B 940B 13.96B 97.33B 37.86B 479B 36.59B 35.8B 1,542B | 9.61B 10.82B 9B 8.15B 15.37B 1,042B 15.49B 108B 42B 532B 40.59B 39.72B 1,711B |
| Net income | 1.93B 2.17B 1.81B 1.64B 3.08B 209B 3.11B 21.67B 8.43B 107B 8.15B 7.97B 343B | 2.3B 2.59B 2.15B 1.95B 3.67B 249B 3.7B 25.82B 10.04B 127B 9.7B 9.5B 409B |
| Net Debt | 413M 465M 387M 350M 660M 44.78B 665M 4.64B 1.8B 22.84B 1.74B 1.71B 73.49B | -1.7B -1.91B -1.59B -1.44B -2.71B -184B -2.73B -19.05B -7.41B -93.82B -7.16B -7.01B -302B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-06 | €202.30 | +0.70% | 213,583 |
| 26-10-05 | €200.90 | -1.66% | 159,633 |
| 26-10-02 | €204.30 | +1.49% | 176,155 |
| 26-10-01 | €201.30 | -1.85% | 237,472 |
| 26-09-30 | €205.10 | -0.82% | 302,223 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UCB Stock
Select your edition
All financial news and data tailored to specific country editions
